IRIS
ROTI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.762
AS - Asia 5.351
EU - Europa 3.959
SA - Sud America 764
AF - Africa 277
Continente sconosciuto - Info sul continente non disponibili 226
OC - Oceania 12
Totale 17.351
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.500
SG - Singapore 1.842
IT - Italia 1.373
CN - Cina 1.347
VN - Vietnam 878
BR - Brasile 555
IE - Irlanda 492
SE - Svezia 432
HK - Hong Kong 418
DE - Germania 346
BD - Bangladesh 259
FR - Francia 248
FI - Finlandia 189
NL - Olanda 189
ZA - Sudafrica 170
UA - Ucraina 156
GB - Regno Unito 140
CA - Canada 136
IN - India 116
TR - Turchia 114
RU - Federazione Russa 107
AT - Austria 102
AR - Argentina 74
JP - Giappone 50
IQ - Iraq 44
MX - Messico 44
PH - Filippine 39
CO - Colombia 34
EC - Ecuador 33
KR - Corea 33
PL - Polonia 33
CI - Costa d'Avorio 32
ES - Italia 29
ID - Indonesia 28
BE - Belgio 25
PK - Pakistan 25
TH - Thailandia 23
VE - Venezuela 23
CR - Costa Rica 21
LT - Lituania 18
UZ - Uzbekistan 18
CZ - Repubblica Ceca 17
EG - Egitto 13
SA - Arabia Saudita 13
TW - Taiwan 13
IR - Iran 12
JM - Giamaica 12
PY - Paraguay 12
TN - Tunisia 12
CL - Cile 11
KE - Kenya 11
MA - Marocco 11
UY - Uruguay 11
DZ - Algeria 9
IL - Israele 9
AU - Australia 8
NI - Nicaragua 8
NP - Nepal 8
AZ - Azerbaigian 7
JO - Giordania 7
KZ - Kazakistan 7
PA - Panama 7
RO - Romania 7
SV - El Salvador 7
TT - Trinidad e Tobago 7
GT - Guatemala 6
MY - Malesia 6
PE - Perù 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
CH - Svizzera 5
ET - Etiopia 5
HU - Ungheria 5
KG - Kirghizistan 5
LU - Lussemburgo 5
RS - Serbia 5
AL - Albania 4
CW - ???statistics.table.value.countryCode.CW??? 4
DK - Danimarca 4
GR - Grecia 4
HR - Croazia 4
LB - Libano 4
OM - Oman 4
SY - Repubblica araba siriana 4
BB - Barbados 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
GP - Guadalupe 3
HN - Honduras 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
SC - Seychelles 3
BO - Bolivia 2
CY - Cipro 2
KH - Cambogia 2
KW - Kuwait 2
LV - Lettonia 2
NG - Nigeria 2
NO - Norvegia 2
Totale 17.105
Salva come PNG Salva come JPEG
Città #
Singapore 954
Ashburn 868
San Jose 704
Dallas 497
Dublin 491
Chandler 472
Hong Kong 396
Santa Clara 394
Parma 326
Beijing 298
Council Bluffs 280
Ho Chi Minh City 259
Boardman 241
Hanoi 198
Johannesburg 160
Jacksonville 136
Los Angeles 135
Ann Arbor 126
New York 126
Lauterbourg 124
Milan 119
Dearborn 107
Munich 100
Princeton 91
Vienna 86
Nanjing 85
Bologna 83
Shanghai 81
Izmir 73
Hefei 70
Buffalo 64
Wilmington 62
Rome 57
Helsinki 56
São Paulo 56
Grafing 53
Shenyang 51
San Mateo 50
Chicago 49
Marseille 49
Toronto 45
Jinan 44
Nanchang 43
Moscow 42
Phoenix 42
Haiphong 39
Columbus 37
Da Nang 37
Montreal 37
Seattle 37
Reggio Emilia 35
Turku 33
Abidjan 32
Hebei 32
Tokyo 30
Amsterdam 29
Frankfurt am Main 28
Guangzhou 28
Modena 28
Atlanta 27
Brooklyn 26
Tianjin 26
Verona 26
Changsha 25
London 25
Nuremberg 25
Brescia 23
Denver 23
Seoul 23
The Dalles 23
Des Moines 22
Houston 22
Kunming 22
Warsaw 22
Brussels 21
Rio de Janeiro 21
Florence 20
Pune 20
Baghdad 19
Poplar 19
San Francisco 19
North Bergen 18
Orem 18
Bremen 17
Fremont 17
Turin 17
Brasília 16
Hải Dương 16
Jiaxing 16
Jakarta 15
Tashkent 15
Bengaluru 14
Biên Hòa 14
Mexico City 14
Naples 14
Perugia 14
San José 14
West Jordan 14
Charlotte 13
Guayaquil 13
Totale 10.093
Salva come PNG Salva come JPEG
Nome #
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 276
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 270
Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis 262
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 257
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 244
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 227
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 225
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 214
227P Sexual dimorphism in immune profile of early and advanced NSCLC 213
Impact of the rs1024611 polymorphism of ccl2 on the pathophysiology and outcome of primary myelofibrosis 201
Genetics of Darier’s Disease: New Insights into Pathogenic Mechanisms 199
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 198
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 194
Targeting oncogenic Notch signaling with SERCA inhibitors 193
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 187
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 186
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 183
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia 178
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML 177
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 176
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 171
CAD204520 Targets NOTCH1 PEST Domain Mutations in Lymphoproliferative Disorders 170
Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia 168
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 165
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 164
Angiopoietins expression by human myeloma cells 164
Venetoclax and bortezomib in relapsed/refractory early t-cell precursor acute lymphoblastic leukemia 164
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 164
Targeting Notch Trafficking and Processing in Cancers 163
Acute lymphoblastic leukaemia 158
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 158
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia 157
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 156
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 156
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 155
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 153
Acute lymphoblastic leukaemia in Noonan syndrome. 151
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 150
CD26 is differentially expressed throughout the life cycle of infantile hemangiomas and characterizes the proliferative phase 144
Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML 144
SERCA MODULATION COUNTERACTS GLUCOCORTICOID RESISTANCE IN T-ALL 142
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 142
The Atypical Protein Kinase WNK1 Controls Leukemia Progression in TAL/LMO T-Cell Acute Lymphoblastic Leukemia 141
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 141
THERAPEUTIC TARGETING OF NOTCH SIGNALING PATHWAY IN HEMATOLOGICAL MALIGNANCIES 141
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia 140
SELECTIVE BLOCKADE OF ONCOGENIC NOTCH1 WITH THE NEW SERCA INHIBITOR CAD204520 139
Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro 138
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 137
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia 137
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 136
Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells 135
A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome 134
Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia 133
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling 131
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 130
Activating somatic and germline TERT promoter variants in myeloid malignancies 129
Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia 125
IL-7 is produced by myeloma cells in presence of IL-6 124
Multiple myeloma patient with unusual extramedullary involvement 124
Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia. 124
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 124
Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition 123
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 122
Osteopontin is produced by human multiple myeloma cells 122
Selective Blockade of Oncogenic NOTCH1 with the New SERCA Inhibitor CAD204520 in T-cell Acute Lymphoblastic Leukemia 120
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 120
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 118
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes 115
Multiple Myeloma patient with unusual extramedullary involvement 113
Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia 113
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 113
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6 112
WO/2016/073708 112
Multiple myeloma patient with unusual extramedullary involvement 112
Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL 112
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 110
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 110
Leukemia-specific delivery of mutant NOT CH1 targeted therapy 109
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 109
Bone marrow endothelial cells carry BCR/ABL fusion gene from chronic myeloid leukemia patients. 108
IL-7 is produced by myeloma cells in presence of IL-6 108
Genetic and proteomic approaches to identify cancer drug targets. 107
Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia 106
FROM GENOMICS TO CHEMOGEGNOMICS IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA 104
T(10;11)(P13;P14-21) PICALM-MLLT10 ACUTE LEUKEMIA: CHARACTERIZATION OF TWO CASES WITH DIFFERENT PHENOTYPIC PRESENTATION 104
Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: From current standards to precision medicine 104
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 104
Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy with Thyroid Carcinoma Cells: Novel Translational Insights 101
Genetic profile of acute lymphoblastic leukemia in a patient with the noonan syndrome 99
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma 96
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. 94
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 94
Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520 93
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 92
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 92
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study 91
e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia 91
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 90
The Folate Cycle Enzyme MTHFR is a Critical Regulator of Cell Response to MYC-Targeting Therapies 90
Totale 14.415
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.260
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.260
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022474 0 0 0 15 7 64 72 55 27 40 32 162
2022/20231.922 219 191 106 124 206 206 32 117 585 7 82 47
2023/2024987 50 64 29 41 85 184 124 80 40 72 72 146
2024/20253.056 90 164 215 235 337 246 145 137 350 251 275 611
2025/20267.339 582 537 1.006 669 936 440 688 322 976 585 356 242
2026/20271.769 284 415 507 563 0 0 0 0 0 0 0 0
Totale 17.351